Metformin to Treat Cancer: Misstep in Translational Research from Observational Studies.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Epidemiology

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/EDE.0000000000000634PMID 28166103
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women

  2017cited by this paper
• Metformin use and survival after colorectal cancer: A population‐based cohort study

  2016cited by this paper
• Metformin use and survival from lung cancer: A population-based cohort study.

  2016cited by this paper
• Sleep and nighttime energy consumption in early childhood: a population‐based cohort study

  2015cited by this paper
• Metformin for pancreatic cancer.

  2015cited by this paper
• No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study

  2015cited by this paper
• No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK

  2015cited by this paper
• Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

  2015cited by this paper
• Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies

  2015cited by this paper
• The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes

  2015cited by this paper
• The Use of Metformin in Patients with Prostate Cancer and the Risk of Death

  2014cited by this paper
• Metformin exposure and disseminated disease in patients with colorectal cancer.

  2014cited by this paper
• Metformin Does Not Affect Cancer Risk: A Cohort Study in the U.K. Clinical Practice Research Datalink Analyzed Like an Intention-to-Treat Trial

  2014cited by this paper
• The effect of metformin on breast cancer outcomes in patients with type 2 diabetes

  2014cited by this paper
• Statin strikeout.

  2014cited by this paper
• Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas

  2014cited by this paper
• Simvastatin in moderate-to-severe COPD.

  2014cited by this paper
• Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders

  2014cited by this paper
• Simvastatin in moderate-to-severe COPD.

  2014cited by this paper
• Association Between Metformin Therapy and Mortality After Breast Cancer

  2013cited by this paper
• Association between metformin use and risk of prostate cancer and its grade.

  2013cited by this paper
• Use of Metformin and Survival of Diabetic Women with Breast Cancer

  2013cited by this paper
• Case–control analysis on metformin and cancer of the esophagus

  2013cited by this paper
• The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes

  2013cited by this paper
• The Use of Metformin and Colorectal Cancer Incidence in Patients with Type II Diabetes Mellitus

  2013cited by this paper
• Association of metformin use with cancer incidence and mortality: a meta-analysis.

  2013cited by this paper
• Diabetes, metformin use, and colorectal cancer survival in postmenopausal women.

  2013cited by this paper
• The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus

  2012cited by this paper
• Metformin does not alter the risk of lung cancer: a case-control analysis.

  2012cited by this paper
• Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity

  2012cited by this paper
• Metformin and the Risk of Cancer

  2012cited by this paper
• The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes

  2012cited by this paper
• Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer

  2012cited by this paper
• Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis

  2012cited by this paper
• Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

  2012cited by this paper
• Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis.

  2012cited by this paper
• Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancer

  2012cited by this paper
• Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan.

  2012cited by this paper
• Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

  2011cited by this paper
• Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

  2011cited by this paper
• Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

  2011cited by this paper
• Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis

  2010cited by this paper
• Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes

  2010cited by this paper
• Metformin in breast cancer: time for action.

  2009cited by this paper
• Immortal time bias in pharmaco-epidemiology.

  2008cited by this paper
• The impact of time‐dependent bias in proportional hazards modelling

  2008cited by this paper
• Immortal time bias in observational studies of drug effects

  2007cited by this paper
• Quantifying the impact of survivor treatment bias in observational studies.

  2006cited by this paper
• Metformin and reduced risk of cancer in diabetic patients

  2005cited by this paper
• Inhaled steroids and mortality in COPD: bias from unaccounted immortal time

  2004cited by this paper
• Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies.

  2003cited by this paper

• Emerging uncertainty on the anti-aging potential of metformin.

  2025cites this paper
• Associations of potentially inappropriate medications in older adults with mortality and hospitalizations: methodological challenges in pharmacoepidemiology

  2025cites this paper
• Reassessing the evidence of a survival advantage in Type 2 diabetes treated with metformin compared with controls without diabetes: a retrospective cohort study.

  2022cites this paper
• Metformin and Dementia Risk: A Systematic Review with Respect to Time Related Biases

  2022cites this paper
• Effects of early medication treatment and metformin use for cancer prevention in diabetes patients: a nationwide sample cohort study in Korea using extended landmark time analysis

  2021cites this paper
• Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments

  2021cites this paper
• A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time

  2020cites this paper
• How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias

  2020cites this paper
• Time‐related biases in pharmacoepidemiology

  2020cites this paper
• Metformin and Reduced Risk of Cancer in the Hong Kong Diabetes Registry: Real Effect or Immortal Time Bias?

  2019cites this paper
• Repurposed Biguanide Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of Intracellular Chloride Channel 1 Activity

  2019cites this paper
• Immortal Time Bias in Epidemiology

  2019cites this paper
• Glucose‐lowering medications and the risk of cancer: A methodological review of studies based on real‐world data

  2019cites this paper
• More recent, better designed studies have weakened links between antidiabetes medications and cancer risk

  2019cites this paper
• Studying the Effects of Nonindicated Medications on Cancer: Etiologic versus Action-Focused Analysis of Epidemiologic Data

  2018cites this paper
• A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study

  2018cites this paper
• Beyond renoprotective impact; ameliorative effects of metformin on malignancies

  2018cites this paper
• Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability

  2018cites this paper
• Involvement of organic cation transporter 2 in the metformin-associated increased lactate levels caused by contrast-induced nephropathy.

  2018cites this paper
• High dose targeted delivery on cancer sites and the importance of short-chain fatty acids for metformin's action: Two crucial aspects of the wonder drug.

  2018cites this paper
• Diabetes drugs and the incidence of solid cancers: a survey of the current evidence

  2017cites this paper